logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12491364 B1

PDFFull Text
Date of Patent:
Dec. 09, 2025

Filed:

Apr. 11, 2022

Monitoring of neuromodulation using biomarkers

Applicant:

Medtronic Ireland Manufacturing Unlimited Company, Dublin, IE;

Inventors:

Ayala Hezi-Yamit, Windsor, CA (US);

Rudy A. Beasley, Rohnert Park, CA (US);

Susan Thornton Edwards, Santa Rosa, CA (US);

Lori Garcia, Santa Rosa, CA (US);

Michele Lee Silver, Hamden, CT (US);

Christopher W. Storment, Sonoma, CA (US);

Carol M. Sullivan, Litchfield Park, AZ (US);

Joseph A. Traina, Napa, CA (US);

Stefan Stoyanov Tunev, Santa Rosa, CA (US);

Assignee:

Medtronic Ireland Manufacturing Unlimited Company, Dublin, IE;

Attorney:

Shumaker & Sieffert, P.A.

Primary Examiner:

Pamela M Bays

Int. Cl.
CPC ...
A61N 1/36 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61B 5/15 (2006.01); A61B 5/20 (2006.01); A61B 18/14 (2006.01); A61B 5/157 (2006.01); A61B 10/00 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01); A61N 1/05 (2006.01); A61N 1/32 (2006.01);
U.S. Cl.
CPC ...
A61N 1/3606 (2013.01); A61B 5/14503 (2013.01); A61B 5/14546 (2013.01); A61B 5/15003 (2013.01); A61B 5/201 (2013.01); A61B 5/6852 (2013.01); A61B 18/1492 (2013.01); A61N 1/36121 (2013.01); A61B 5/1405 (2013.01); A61B 5/15 (2013.01); A61B 5/150229 (2013.01); A61B 5/150992 (2013.01); A61B 5/157 (2013.01); A61B 5/20 (2013.01); A61B 5/4035 (2013.01); A61B 5/4836 (2013.01); A61B 5/4848 (2013.01); A61B 5/6858 (2013.01); A61B 10/0045 (2013.01); A61B 10/007 (2013.01); A61B 2018/00166 (2013.01); A61B 2018/00214 (2013.01); A61B 2018/00232 (2013.01); A61B 2018/00279 (2013.01); A61B 2018/00345 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/0212 (2013.01); A61N 1/05 (2013.01); A61N 1/0551 (2013.01); A61N 1/32 (2013.01); A61N 1/3605 (2013.01); A61N 1/36135 (2013.01); G01N 2800/347 (2013.01);
Abstract

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. A method can include transluminally delivering a distal portion of an elongated shaft of a catheter to a target renal blood vessel and at least partially inhibiting sympathetic neural activity of a renal nerve. The method includes determining a post-neuromodulation level of one or more biomarkers after at least partially inhibiting the sympathetic neural activity of the renal nerve, wherein the level of the one or more biomarkers directly or indirectly correlates with sympathetic nervous activity in the patient. The method can include comparing the post-neuromodulation level to a predetermined level for the one or more biomarkers, wherein the renal neuromodulation procedure is classified as at least partially successful if the post-neuromodulation level differs from the predetermined level.

Find Patent Forward Citations

Loading…